东宝生物(300239) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥135,596,826.05, representing an increase of 18.65% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥6,193,157.07, a significant increase of 64.31% year-on-year[3] - The basic earnings per share for Q3 2021 was ¥0.0119, up by 65.28% compared to the same quarter last year[3] - Operating revenue increased to ¥412,267,239.59, up 36.93% from ¥301,069,330.26, primarily due to increased sales of gelatin and collagen products[10] - The company achieved operating revenue of ¥412,267,239.59, an increase of 36.93% year-over-year, and a net profit attributable to shareholders of ¥13,744,660.50, up 30.30% year-over-year[20] - Net profit for Q3 2021 was CNY 13,670,658.88, representing a 31.0% increase from CNY 10,369,752.85 in Q3 2020[29] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥1,615,264,326.62, reflecting a growth of 13.92% from the end of the previous year[3] - The company's total liabilities decreased to CNY 215,370,256.95 from CNY 419,750,969.84 year-on-year[28] - The company reduced short-term borrowings to ¥39,825,314.15 from ¥90,916,828.04 at the end of 2020[26] Cash Flow - The company's cash flow from operating activities for the year-to-date period decreased by 24.99% to ¥25,252,201.87[3] - Cash received from operating activities decreased by 45.16% to ¥7,662,867.40 from ¥13,972,579.86, mainly due to reduced government subsidies[11] - The net cash flow from operating activities for Q3 2021 was ¥25,252,201.87, a decrease from ¥33,666,271.86 in the previous year[33] - The net cash flow from investing activities was -¥121,263,088.04, compared to -¥120,247,612.20 in the same period last year[33] - The net cash flow from financing activities increased to ¥254,532,800.08 from ¥86,936,547.36 year-over-year[33] Equity and Shareholding - The company reported a 41.41% increase in total equity attributable to shareholders, reaching ¥1,399,894,069.67 compared to the end of the previous year[3] - The number of ordinary shareholders at the end of the reporting period was 28,272, with no preferred shareholders[14] - The company has a shareholding structure where the top 10 shareholders include significant stakes from state-owned and private entities, indicating a diverse ownership base[15] - The report indicates that the company has implemented a three-year unlocking schedule for equity incentive shares, with unlocking ratios of 40%, 30%, and 30%[18] Investments and Expenditures - Research and development expenses increased by 80.76% to ¥10,133,540.77, driven by new project investments[8] - The company completed the acquisition of a 60% stake in Qingdao Yiqing Biotechnology Co., Ltd. for a total consideration of ¥27,186.39 million, aiming to enhance its health industry layout and core competitiveness[22] - Investment cash outflows surged by 1230.59% to ¥74,406,780.00 from ¥5,592,000.00, primarily due to increased equity investment expenditures[11] Other Financial Metrics - Other income surged by 79.18% to ¥8,303,857.10 from ¥4,634,464.64, mainly due to increased government subsidies and deferred income[10] - Investment income reported a loss of ¥1,675,448.37, worsening by 47.28% compared to a loss of ¥1,137,626.38, attributed to recognized investment losses from long-term equity investments[10] - Cash paid for various taxes increased by 149.30% to ¥28,605,143.89 from ¥11,474,236.26, driven by higher operating revenue and profit[11] Share Restrictions and Governance - The report highlights that the company is subject to restrictions on share transfers for executives, limiting annual transfers to 25% of their holdings[18] - The company has not disclosed any related party relationships among the top shareholders, which may impact governance and control[15] - The report indicates that the company is preparing for the release of restricted shares on December 15, 2021, for several shareholders, which may affect stock liquidity[18]